Australian Pro Triathlete to Receive 4-Year Ban from ASADA for Doping

By Wires August 5, 2016

0 Comments

The Australian Sports Anti-Doping Authority (ASADA) is expected to issue an official punishment to Australian pro triathlete Lisa Marangon, on what is expected to be a maximum ban of four years. The 36-year old Marangon was notified five months ago that she tested positive for the banned performance-enhancing drug, Ostarine, after her 5^th place finish at Challenge Melbourne.

The multi Ironman 70.3 champion issued her own official statement to US triathlon website Triathlete.com on Friday, July 29.

“It is with a heavy heart that I wish to announce that in January of this year I tested positive for a banned substance, called ‘Ostarine.’ As will be evident over the coming period of time, I maintain that I did not knowingly take this substance and that I am the victim of tampering and or sabotage at the hands of person/s who wish to cause me harm…”

Marangon denied any intentional wrongdoing of the performance-enhancing drug in question (PED) in question:

“I will continue to protest my innocence, regardless of the findings and sanctions which are in the process of being handed down against me. Whilst I am devastated that this will likely bring about the end of my professional triathlon career, I would like to state clearly that I have been completely honest and fully cooperative with ASADA during the investigative process, and hold no ill will toward that agency, the race or the sport.

As stated above, I will continue to try to clear my name and hopefully also serve as an example to others to be more careful in the future.” – Lisa Marangon, Friday, July 29, 2016

Ostarine, also known as MK-2866 is in class of drugs called SARMS, which stands for selective androgen receptor modulators. Ostarine binds to your muscles receptors and causes steroid-like muscle growth without side effects. These gains are absolutely “keepable” and maintainable after use is discontinued, as long as workouts stay consistent and diet remains on track.